#United States #Henderson #VolitionRx #Nu.Q® NETs #Sepsis Management

VolitionRx Announces Virtual Investor Event on Sepsis Management

VolitionRx Limited, a pioneering player in the field of epigenetics, has officially announced a virtual event tailored for investors. Scheduled for February 14, 2025, at 8:00 AM ET, this event promises to unveil important advancements in the realm of sepsis management. The spotlight will be on the company’s cutting-edge biomarker, Nu.Q® NETs H3.1, which is showing significant potential in early diagnosis and monitoring of sepsis, a life-threatening condition that demands timely medical intervention.

During the event, key figures from VolitionRx will take the stage, including Dr. Andrew Retter, the Chief Medical Officer, and Gael Forterre, the Chief Commercial Officer. Dr. Retter will delve deeply into the findings derived from a notable study highlighting Nu.Q® NETs H3.1's capability as an independent predictor for early mortality and organ dysfunction in sepsis patients. This groundbreaking biomarker not only identifies patients at risk but also aids in determining the necessity for renal replacement therapy. Such advancements suggest a transformative shift in how sepsis could be managed in medical settings, fostering the potential for early intervention and improved patient outcomes.

Mr. Forterre will share insights regarding VolitionRx's journey towards commercialization, emphasizing strategies involving both licensing agreements and diversified sales efforts, aimed at broadening access to their innovative diagnostic tools. Following the formal presentations, the event will include a live Q&A session, allowing participants to engage directly with the leadership team and seek additional clarification on the presented materials.

About the Speakers

Dr. Andrew Retter

Dr. Retter boasts an impressive academic and professional background, holding qualifications including BSc (Hons), MBBS, FRCP, FRCPath (Haem), and DICM. He serves as a Consultant in Critical Care and has been instrumental in clinical research concerning innovative diagnostic tools for sepsis and other conditions. His accumulated experience is characterized by an active role in various clinical trials, alongside an impressive catalog of published studies in esteemed medical journals.

Gael Forterre

Gael Forterre, appointed as Chief Commercial Officer in 2021, has a wealth of experience in building commercialization strategies across diverse sectors. His track record includes notable leadership roles in high-growth companies, focusing on scaling operations and strategic investments. With a strong educational background, including a master’s degree in finance and dual MBAs from prestigious institutions, Forterre is poised to guide VolitionRx towards expansive growth in the diagnostic market.

About VolitionRx

VolitionRx is committed to revolutionizing the landscape of disease diagnosis through its innovative blood tests aimed at improving early detection and monitoring for various diseases, including cancers and conditions associated with NETosis. With a global footprint that includes research and development hubs in Belgium and laboratories in the US and London, the company is primed to make significant strides in medical innovation. Through its efforts, VolitionRx aims to enhance life quality and outcomes for patients worldwide, enabling earlier interventions and more tailored management of critical illnesses.

Stay tuned for this highly informative event that showcases how VolitionRx is setting new standards in the field of sepsis management and medical diagnostics.